Catalent Inc. said June 2 that Charles Lickfold, a 20-year digital and information technology veteran, will take over as the Somerset-based company’s chief information officer.
Lickfold will be responsible for all of Catalent’s global IT services, replacing John McGill, who will retire in September after assisting in the transition.
“At the heart of any company is its function to interact digitally, communicate globally, and protect internal systems to ensure the integrity of the business. In recent months, the ability to work remotely has been put to the test, and our investments in information technology have been central to Catalent’s success in continuing to function efficiently,” said Alessandro Maselli, the company’s president and chief operating officer, in a statement. “We welcome Charlie to Catalent and look forward to gaining the benefit of his experience and expertise. I also want to thank John for his leadership and contribution to the company over the last seven years, and wish him all the best in his retirement.”
Before joining Catalent, Lickfold served as CIO at Alcami, Avara Pharmaceutical Services, and Gilbarco Veeder-Root, as well as vice president and IT chief at Patheon. He began his career as a management consult at Ernst & Young.
Catalent operates 40 facilities around the world and employs about 13,500 people, including more than 2,400 scientists. The company said it generated revenues of $2.5 billion in fiscal 2019.
In April, Catalent said it was working with Johnson & Johnson’s Janssen Pharmaceutical Cos. on the production of a COVID-19 vaccine. Through its Biologics business unit, Catalent will accelerate the availability of manufacturing capacity, and prepare for large-scale commercial manufacturing, at its Bloomington, Ind. facility for J&J’s lead vaccine candidate.
The following month, Catalent announced it formed a partnership with Arcturus Therapeutics Holdings Inc. to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19). Under the arrangement, the vaccine will be manufactured at Catalent’s drug substance biomanufacturing facility in Madison, Wis. Human clinical studies will also be conducted at that facility and, if successful, the vaccine will be commercialized.